• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Obstetrics

Decreased risk of ovarian cancer in women who have breastfed

byAlex ChanandRavi Shah, MD MBA
April 17, 2020
in Obstetrics, Oncology, Pediatrics
Reading Time: 2 mins read
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Share on FacebookShare on Twitter

1. Breastfeeding was found to be significantly associated with decrease risk of invasive ovarian cancer, including high-grade serous and endometroid cancer.

Evidence Rating: 2 (Good)

Ovarian cancer is a significant contributor to female mortality, with 5-year survival following diagnosis being less than 50%. Prevention is critical for reducing disease mortality, but currently, few modifiable risk factors beyond oral contraceptive use have been identified. Breast feeding has been reported as a potential modifiable risk factor, with some studies finding a negative association between breast feeding and epithelial ovarian cancer development. The relationship between the two is not well characterized however, as prior studies often had insufficient sample sizes. In this pooled analysis, data of 9973 women with ovarian cancer and 13 843 controls from the Ovarian Cancer Association Consortium was included to further investigate this association. Data was collected between 1989 and 2009, with exposures of interest including duration of breastfeeding, age at first and last breastfeeding, and years since last breastfeeding for example. A history of breastfeeding was associated with an overall 24% lower risk of invasive ovarian cancer (odds ratio [OR], 0.76; 95% CI, 0.71-0.80), and 28% reduction of borderline tumor risk, and was independent of parity. Among invasive diseases, researchers observed statistically significant associations for high-grade serous (OR, 0.75; 95% CI, 0.70-0.81), endometrioid (OR, 0.73; 95% CI, 0.64-0.84), and clear cell tumors (OR, 0.78; 95% CI, 0.64-0.96). The protective effect was more pronounced with greater duration of breastfeeding (18% risk reduction for 1 to 3 months, 34% reduction for 12 months or greater), and reduction of cancer risk persisted for decades, with significantly lower risk even 30 years later. This study represents the largest study investigating breastfeeding and ovarian cancer risk, providing strong evidence for breastfeeding as a potentially modifiable risk factor for cancer development. Future research to better characterize the biological mechanisms underlying risk reduction are encouraged to potentially reveal further therapeutic targets or screening measures related to ovarian cancer.

Click to read the study in JAMA Oncology

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Early menarche and later menopause are associated with increased ovarian cancer risk

2 Minute Medicine Rewind February 9, 2026

An ultrasound test may more reliably detect ovarian cancer in premenopausal women than the Risk of Malignancy Index

Tags: breastfeedingclear cell tumorendometrioid tumorovarian cancer
Previous Post

Addition of claims-based frailty index enhances current Medicare cost prediction model

Next Post

#VisualAbstract: A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

RelatedReports

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Chronic Disease

Early menarche and later menopause are associated with increased ovarian cancer risk

February 13, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind February 9, 2026

February 9, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Chronic Disease

An ultrasound test may more reliably detect ovarian cancer in premenopausal women than the Risk of Malignancy Index

February 6, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind February 2, 2026

February 2, 2026
Next Post
#VisualAbstract: A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

#VisualAbstract: A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

#VisualAbstract: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

#VisualAbstract: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.